Skip to main content

Table 3 Pre-treatment serum concentration and urinary excretion of MIF in patients with proliferative and non-proliferative glomerulonephritis (GN)

From: Macrophage migration inhibitory factor urinary excretion revisited – MIF a potent predictor of the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis

  

Serum MIF (ng/ml)

Urinary MIF (ng/mg Cr)

Proliferative GN

Mean ± SD

2.2 ± 1.0

4.2 ± 2.1

Median (range)

1.9 (1.1–3.4)

3.6a,b (2.0–8.1)

Non-proliferative GN

Mean ± SD

1.8 ± 0.3

3.0 ± 1.9

Median (range)

1.3 (1.0–2.4)

2.2c (1.7–4.3)

Pooled

Mean ± SD

1.7 ± 0.8

3.7 ± 1.9

Median (range)

1.7 (1.0–3.3)

3.2 (1.7–8.1)

Healthy

Mean ± SD

0.2 ± 0.01

0.5 ± 0.02

Median (range)

0.2 (0.18–0.21)

0.5 (0.4–0.5)

  1. Differences were considered significant for P < 0.05 (Kruskal-Wallis ANOVA)
  2. aProliferative GN versus Non-proliferative GN
  3. bProliferative GN versus Healthy patients
  4. cNon- proliferative GN before versus Healthy
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us